NCT00458159View on ClinicalTrials.gov

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

PHASE1TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 1, 2007

Primary Completion Date

October 1, 2008

Study Completion Date

December 1, 2008

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

CC-11006

Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.

Trial Locations (7)

10021

New York Presbyterian Hospital-Weill Cornell Medical College, New York

20817

Center for Cancer and Blood Disorders, Bethesda

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

44195

The Cleveland Clinic Foundation, Cleveland

77030

MD Anderson Cancer Center, Houston

46202-5149

Indiana University Medical Center, Indianapolis

27157-1082

Wake Forest University School of Medicine Bowman Gray Campus, Comprehensive Cancer Center, Winston-Salem

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT00458159 - A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter